About
Mineralys Therapeutics, Inc. Common Stock (NASDAQ:MLYS) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 24 2026
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
Mar 12 2026
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Mar 9 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Mar 9 2026
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
Feb 12 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Financials
Revenue
$0
Market Cap
$2.33 B
EPS
-2.29
